Navigation Links
OncoGenex to Present at Credit Suisse Healthcare Investor Conference

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 5, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2013 at 8:30 a.m. MST at the Phoenician Hotel in Scottsdale, Arizona.

A live audio webcast can be accessed through the Investor Relations page of the OncoGenex website at The webcast replay will be archived for 60 days.

Highlights from the presentation can be followed on the new OncoGenex Investor Relations Twitter account at:

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
2. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
3. MGB Biopharma to Present at Bio-Europe 2013
4. First Annual Michael SanInocencio Lennox-Gastaut Syndrome Research Award Presented at Annual Meeting of the Child Neurology Society
5. RSC New England Clinicians to Present at RESOLVE New England’s 20th Annual Conference on November 2nd, 2013
6. MiMedx To Present At Canaccord Genuity Medical Technology And Diagnostics Forum
7. Successful Pediatric Studies: Key Study Design and Operational Considerations, a New Webinar Presented by Premier Research and Xtalks
8. ClearPath Workforce Management Expert to Present on Contractor Payroll, Engagement and Compliance as Part of Institute for Human Resources Virtual Conference
9. Z Trim to Present at the 2013 Clean Label Conference
10. Vet-Stem, Inc. Founder and CEO Presents at TargetMeeting’s 3rd World Drug Discovery Online Conference
11. Rancho BioSciences will present the tranSMART open source platform at TM Forum’s Digital Disruption 2013, Oct 28-31, San Jose
Post Your Comments:
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") ( ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):